195 related articles for article (PubMed ID: 28825224)
1. Estrogen receptor quantitative measures and breast cancer survival.
Hill DA; Barry M; Wiggins C; Nibbe A; Royce M; Prossnitz E; Lomo L
Breast Cancer Res Treat; 2017 Dec; 166(3):855-864. PubMed ID: 28825224
[TBL] [Abstract][Full Text] [Related]
2. Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.
Kensler KH; Poole EM; Heng YJ; Collins LC; Glass B; Beck AH; Hazra A; Rosner BA; Eliassen AH; Hankinson SE; Winer EP; Brown M; Tamimi RM
J Natl Cancer Inst; 2019 Jul; 111(7):700-708. PubMed ID: 30445651
[TBL] [Abstract][Full Text] [Related]
3. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
[TBL] [Abstract][Full Text] [Related]
4. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2017 Sep; 165(2):391-402. PubMed ID: 28601929
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
7. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
8. Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort.
Elebro K; Borgquist S; Simonsson M; Markkula A; Jirström K; Ingvar C; Rose C; Jernström H
Clin Cancer Res; 2015 Aug; 21(16):3640-50. PubMed ID: 25904752
[TBL] [Abstract][Full Text] [Related]
9. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
10. High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
Wang Z; Katsaros D; Biglia N; Shen Y; Fu Y; Loo LWM; Jia W; Obata Y; Yu H
Breast Cancer Res Treat; 2018 Sep; 171(2):261-271. PubMed ID: 29845475
[TBL] [Abstract][Full Text] [Related]
11. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
12. High expression of LMTK3 is an independent factor indicating a poor prognosis in estrogen receptor α-positive breast cancer patients.
Asano T; Sato S; Yoshimoto N; Endo Y; Hato Y; Dong Y; Takahashi S; Fujii Y; Toyama T
Jpn J Clin Oncol; 2014 Oct; 44(10):889-97. PubMed ID: 25163465
[TBL] [Abstract][Full Text] [Related]
13. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
[TBL] [Abstract][Full Text] [Related]
14. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor expression and breast cancer mortality in a population-based prospective cohort.
Elebro K; Bendahl PO; Jernström H; Borgquist S
Breast Cancer Res Treat; 2017 Oct; 165(3):645-657. PubMed ID: 28643022
[TBL] [Abstract][Full Text] [Related]
16. Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors.
Parise CA; Caggiano V
Breast Cancer Res Treat; 2017 Oct; 165(3):743-750. PubMed ID: 28689363
[TBL] [Abstract][Full Text] [Related]
17. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.
Mittendorf EA; Vila J; Tucker SL; Chavez-MacGregor M; Smith BD; Symmans WF; Sahin AA; Hortobagyi GN; Hunt KK
JAMA Oncol; 2016 Jul; 2(7):929-36. PubMed ID: 26986538
[TBL] [Abstract][Full Text] [Related]
18. Effects of tumor-specific CAP1 expression and body constitution on clinical outcomes in patients with early breast cancer.
Bergqvist M; Elebro K; Sandsveden M; Borgquist S; Rosendahl AH
Breast Cancer Res; 2020 Jun; 22(1):67. PubMed ID: 32560703
[TBL] [Abstract][Full Text] [Related]
19. Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER
van der Velden BHM; Elias SG; Bismeijer T; Loo CE; Viergever MA; Wessels LFA; Gilhuijs KGA
Clin Cancer Res; 2017 Nov; 23(21):6505-6515. PubMed ID: 28790119
[No Abstract] [Full Text] [Related]
20. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
